Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 40,924 shares, an increase of 443.5% from the March 31st total of 7,530 shares. Based on an average daily trading volume, of 2,581,923 shares, the short-interest ratio is currently 0.0 days. Currently, 2.1% of the shares of the stock are short sold.

Biodexa Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ BDRX opened at $3.30 on Friday. The firm’s 50-day moving average price is $4.23 and its 200-day moving average price is $15.61. Biodexa Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $96.50.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings data on Friday, March 27th. The company reported $3.52 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.53.

Wall Street Analyst Weigh In

BDRX has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.